KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Financing Activities (2016 - 2025)

Pfizer (PFE) has disclosed Cash from Financing Activities for 17 consecutive years, with $596.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 111.65% to $596.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.3 billion, a 39.88% increase, with the full-year FY2025 number at -$10.3 billion, up 39.88% from a year prior.
  • Cash from Financing Activities was $596.0 million for Q4 2025 at Pfizer, up from -$2.5 billion in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $27.2 billion in Q3 2023 to a low of -$9.8 billion in Q4 2022.
  • A 5-year average of -$1.5 billion and a median of -$3.0 billion in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 256.23% in 2021, then soared 978.33% in 2023.
  • Pfizer's Cash from Financing Activities stood at -$6.5 billion in 2021, then tumbled by 51.88% to -$9.8 billion in 2022, then surged by 155.42% to $5.4 billion in 2023, then tumbled by 193.97% to -$5.1 billion in 2024, then skyrocketed by 111.65% to $596.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Cash from Financing Activities are $596.0 million (Q4 2025), -$2.5 billion (Q3 2025), and -$3.2 billion (Q2 2025).